In addition, combining anti-LAG-3 mAbs with anti-PD-1 mAbs has been shown to enhance IFN-γ production and the cytotoxic capacity of T cells, leading to robust control of tumor growth [92]. The gene discussed is LAG3; the disease is neoplasm.